The most common type of ovarian cancer1, called high-grade serous ovarian cancer (HGSOC), is challenging from a therapeutic perspective. By the time most individuals are diagnosed with this type of tumour, it has already spread (metastasized) from the primary site to distant regions, seeding cancer cells in multiple abdominal locations (intraperitoneal sites). At that point, symptoms arise because of an accumulation of peritoneal fluid in these areas. Writing in Nature, Vázquez-García et al.2 provide insights into metastatic ovarian cancer.
Competing Interests
G.C. has received grants, research support or is co-investigator in clinical trials by Bristol-Myers Squibb, Celgene, Boehringer Ingelheim, Roche, Tigen Pharma, Iovance and Kite. G.C. has patents in the domain of antibodies and vaccines targeting the tumour vasculature, as well as technologies related to T-cell expansion and engineering for T-cell therapy.
More News
Author Correction: Stepwise activation of a metabotropic glutamate receptor – Nature
Changing rainforest to plantations shifts tropical food webs
Streamlined skull helps foxes take a nosedive